Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genta, a biopharmaceutical company, has reported that the European Patent Office intends to grant two key patents related to the company's intellectual property position on Genasense injection.
Subscribe to our email newsletter
The company has proceeded with grant formalities and validation of the patents. Corresponding patents and applications have issued or are pending worldwide. Together, the patents will provide protection for compositions, sequences, and pharmaceutical uses of Genasense and related compounds that attack Bcl-2, the molecular target of Genasense action.
Raymond Warrell, Jr, CEO of Genta, said: “Genta’s patent estate related to Genasense is extensive, we have detailed plans for securing rapid approval in Europe with positive data this fall.
“The majority of patients enrolled into the Agenda trial, a Phase III trial of Genasense in melanoma that completed accrual earlier this month, originated from Europe. The extended market protection offered by these patents comes at an especially favorable time in the product’s lifecycle.”